Taken together, in newly diagnosed and premalignant myeloma patients, a tenfold lower Dex dose in combination with Spi could be advantageous, although the extent of the therapeutic benefit will differ among patients (Fig. 4M, top panel). Here, CHGA is linked to plasma cell myeloma.